Adalimumab is licensed for the treatment of hidradenitis suppurativa (HS), plaque psoriasis, and other inflammatory diseases. For a study, researchers were to look at the safety of adalimumab given every other week (EOW) and every week (EW) in patients with HS and psoriasis, as well as to look at data from non-dermatologic reasons. During placebo-controlled and open-label research periods, the safety of adalimumab 40-mg EOW versus EW dosage was investigated in patients with HS (three studies), psoriasis (two studies), Crohn’s disease (six studies), ulcerative colitis (three studies), and rheumatoid arthritis (one study).
There were no additional safety hazards or higher incidence of specific adverse events (AEs) associated with EW dosage. In individuals with HS or psoriasis, the overall safety of adalimumab 40-mg EOW and EW was typically equal. In trials of adalimumab for non-dermatologic indications such as Crohn’s disease, ulcerative colitis, and rheumatoid arthritis, the overall AE rates for EW and EOW dosage were comparable.
The safety of adalimumab EW and EOW in patients with HS or psoriasis was comparable and consistent with the predicted adalimumab AE profile. Data comparing adalimumab EW and EOW dose for Crohn’s disease, ulcerative colitis, and rheumatoid arthritis suggest the safety of adalimumab EW dosing in individuals with dermatologic diseases.
Reference:link.springer.com/article/10.1007/s40257-017-0341-6
